INTERFERON-ALPHA-2 (IFN) PLUS HYDROXYUREA FOR TREATMENT OF JUVENILE CHRONIC MYELOGENOUS LEUKEMIA

被引：4
|
作者：
SUTTORP, M
RISTER, M
SCHMITZ, N
机构：
[1] CHRISTIAN ALBRECHTS UNIV KIEL,DEPT PEDIAT,W-2300 KIEL 1,GERMANY
[2] CHRISTIAN ALBRECHTS UNIV KIEL,DEPT INTERNAL MED 2,BONE MARROW TRANSPLANT UNIT,W-2300 KIEL 1,GERMANY
[3] KRANKENHAUS KEMPERHOF,DEPT PEDIAT,W-5400 KOBLENZ,GERMANY
[4] CHRISTIAN ALBRECHTS UNIV KIEL,CHILDRENS HOSP,CHWANENWEG 20,D-24105 KIEL,GERMANY
来源：
MEDICAL AND PEDIATRIC ONCOLOGY | 1994年 / 22卷 / 05期
关键词：
D O I：
10.1002/mpo.2950220513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：358 / 359
页数：2
相关论文
共 50 条
  • [31] Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase or chronic myelogenous leukemia (CML Study II)
    Hehlmann, R
    Heimpel, H
    Hossfeld, DK
    Hasford, J
    Kolb, HJ
    Loffler, H
    Pralle, H
    Queisser, W
    Hochhaus, A
    Tichelli, A
    Fett, W
    Schmitz, N
    Reiter, A
    Griesshammer, M
    Pfeifer, W
    Baumler, M
    Kamp, T
    Tobler, A
    Eimermacher, H
    Kuse, R
    Berger, U
    Ansari, H
    BONE MARROW TRANSPLANTATION, 1996, 17 : S21 - S24
  • [32] Pilot study of interferon alpha receptor (IFN alpha R) expression in patients with chronic myelogenous leukemia (CML).
    Spielberger, R
    Snyder, D
    Forman, SJ
    Niland, J
    Nunez, R
    Domanski, PI
    Colamonici, O
    BLOOD, 1995, 86 (10) : 2100 - 2100
  • [33] Gene transfer of alpha interferon (IFN-alpha) into hematopoietic stem cells in chronic myelogenous leukemia (CML).
    Abraham, NG
    Cook, P
    Feldman, E
    Ahmed, T
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 157 - 157
  • [34] Prospective comparative analysis of adverse effects during the treatment of patients with chronic myelogenous leukemia in chronic phase with interferon alpha, busulfan and hydroxyurea.
    Hochhaus, A
    Berger, U
    Ansari, H
    Hasford, J
    Hehlmann, R
    BLOOD, 1997, 90 (10) : 3997 - 3997
  • [35] INTERFERON-ALPHA THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
    WETZLER, M
    KANTARJIAN, H
    KURZROCK, R
    TALPAZ, M
    AMERICAN JOURNAL OF MEDICINE, 1995, 99 (04): : 402 - 411
  • [36] Interferon alpha (IFN) and cyclic intensive chemotherapy (CIC) for chronic phase (CP) chronic myelogenous leukemia (CML).
    Giles, FJ
    Talpaz, M
    O'Brien, SM
    Rios, MB
    Kantarjian, HM
    BLOOD, 1999, 94 (10) : 274B - 274B
  • [37] Early treatment decisions with interferon alpha (IFN-A) therapy in early chronic phase chronic myelogenous leukemia (CP-CML).
    Sacchi, S
    Kantarjian, K
    Smith, T
    OBrien, S
    Pierce, S
    Kornblau, S
    Beran, M
    Keating, M
    Talpaz, M
    BLOOD, 1997, 90 (10) : 2303 - 2303
  • [38] Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia
    Lacotte, L
    Thierry, A
    Delwail, V
    Dreyfus, B
    Guilhot, F
    ACTA HAEMATOLOGICA, 1999, 102 (03) : 160 - 162
  • [39] USE OF INTERFERON IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
    TALPAZ, M
    SEMINARS IN ONCOLOGY, 1994, 21 (06) : 3 - 7
  • [40] Treatment of chronic myelogenous leukemia with interferon alpha. A decade of experience.
    Freund, M
    Heussner, P
    Hild, F
    Nowak, R
    GroteMetke, A
    Diedrich, H
    Koch, O
    Otremba, B
    vonWussow, P
    Kleine, HD
    Meran, J
    Link, H
    Hinrichs, HF
    Balleisen, L
    Fonatsch, C
    Poliwoda, H
    MEDIZINISCHE KLINIK, 1996, 91 : 18 - &
12345